Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$2.75 USD
-0.06 (-2.14%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $2.70 -0.05 (-1.82%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 241 - 260 ( 400 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life SciencesThis report contains brief updates on the following: BMRN, VYGR, AQST, AXLA, ICPT, IMUX, VRNA, BPMC, MGNX. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q2; AQST-108 Fast Track Designation May Reduce Time for Regulatory Review
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
AQST-108/ Anaphylaxis: IND Submitted; PK Trials to Start by YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
AQST-108 Investigational New Drug Application Filed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R